Bayer

Showing 15 posts of 258 posts found.

Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy

September 24, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …

bayercross3

Bayer buys BlueRock Therapeutics for $600 million

August 9, 2019
Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma

Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …

fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

July 30, 2019
Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …

ipos0_l

FDA expands indication for Eylea to cover all stages of diabetic retinopathy

May 14, 2019
Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma

The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …

Bayer VP elected to two of the firm’s executive committees

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment

Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …

shirelabsus

Takeda ordered to pay Bayer $155.19 million over patent infringement

February 6, 2019
Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate

A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 7, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit

Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …

Bayer to cut 12,000 jobs by 2025

December 6, 2018
Business Services, Manufacturing and Production, Sales and Marketing Bayer, Germany, Jobs, manfucaturing, monsanto, production

German pharma giant Bayer is set to cut 12,000 jobs by 2025 as part of a plan to focus on …

Bayer announces major restructure, 12,000 jobs to go

November 30, 2018
Medical Communications, Sales and Marketing Bayer, job cuts, monsanto, pharma

Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its …

NICE recommends Bayer’s Stivarga for advanced hepatocellular carcinoma

November 29, 2018
Sales and Marketing Bayer, NICE, Stivarga, UK, pharma

The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on …

bayercross3

Bayer’s Jivi approved in Europe for previously treated haemophilia A

November 28, 2018
Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma

Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …

top_10_image

Top Ten most popular articles on Pharmafile.com this week

October 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …

Latest content